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OBJECTIVES We examined effects of immunoglobulin on murine myocarditis induced by encephalomyo-
carditis virus, not pathogenic to humans, and analyzed the plasma cytokine and catecholamine
levels and the changes of the extracellular matrix with or without the treatment.
BACKGROUND We have previously shown that immunoglobulin therapy suppressed murine coxsackievirus
B3 myocarditis by an antiviral effect. However, it is not yet determined whether beneficial
effects of immunoglobulin for myocarditis are due to antiviral effects or to other unknown
effects.
METHODS Antiviral activity of human immunoglobulin (Polyglobin-N) against encephalomyocarditis
virus was determined in vitro. Immunoglobulin (1 g/kg/day) was administered intraperito-
neally to the virus-infected mice daily for two weeks, beginning simultaneously with virus
inoculation in experiment I and on day 14 after virus inoculation in experiment II.
RESULTS Antiviral activity of immunoglobulin could not be detected in the assay of a plaque-reduction
method in vitro. The in vivo study showed that immunoglobulin administration ameliorated
both myocardial necrosis with interstitial fibrin deposition in experiment I and interstitial
fibrosis with the improvement of ventricular remodeling in experiment II by the reduction of
plasma catecholamines, interferon-alpha, and soluble intercellular adhesion molecule-1.
CONCLUSIONS Immunoglobulin therapy could suppress myocarditis associated with the improvement of
extracellular matrix changes by the reduction of neurohumoral activity. (J Am Coll Cardiol
2000;36:1979–84) © 2000 by the American College of Cardiology
The therapeutic efficacy of immunoglobulin in inflamma-
tory and autoimmune diseases has been reported (1–5). The
prophylactic administration of immunoglobulin was re-
ported to be of clinical value against some virus infections,
and this effect was due to the capacity of immunoglobulin to
neutralize the viruses. The successful treatment of idio-
pathic thrombocytopenic purpura with immunoglobulin
appears to result from the blockade of Fc receptors (5) The
rapid effect in children with Kawasaki disease may be due to
the neutralization of a microbial toxin by immunoglobulin
(3) that binds nonspecifically to certain viable regions of the
T-cell-antigen receptor.
Infiltration of the myocardium with inflammatory cells
occurs during infection with a variety of viruses (6,7).
Myofiber necrosis is an important feature of this lesion.
Viral myocarditis is considered a cause of dilated cardiomy-
opathy (6,7). Histologically, myocarditis is manifested by
foci of myocyte necrosis with interstitial inflammation,
whereas cardiomyopathy is characterized by diffuse intersti-
tial fibrosis, myocyte hypertrophy and an absence of acute
inflammation (8). Much attention has recently been focused
on changes of the extracellular matrix in myocardial diseases
(9,10). It is well known that fiber-forming proteins are of
two functional types: mainly structural (collagens and lami-
nin) and mainly adhesive (fibrin, fibronectin and laminin)
(11). All the matrix proteins are secreted locally by cells in
contact with the matrix. The extracellular matrix was
thought to serve as a relatively inert frame to stabilize the
physical structure of myocytes. But it is now clear that the
matrix plays an active role in regulating the behavior of the
cells in myocarditis and other myocardial diseases (11).
We have previously demonstrated (12) that immunoglob-
ulin therapy suppressed murine myocarditis induced by
coxsackievirus B3, the most cardiotropic agent in humans.
However, it is not yet determined whether the beneficial
effects are due to antiviral effects or other, unknown effects.
Thus, in the present study, we examined the effects of
immunoglobulin on experimental murine myocarditis in-
duced by encephalomyocarditis virus (13), which may not
infect humans. We also analyzed the plasma catecholamine
and cytokine levels, the most sensitive markers for myocar-
dial dysfunction, and the changes of the extracellular matrix
with and without the treatment.
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METHODS
In vitro study. Immunoglobulin (Polyglobin-N) was
kindly supplied by Bayer Co., Ltd., Japan. Antiviral activity
against encephalomyocarditis (EMC) virus was assayed by a
plaque-reduction method, as previously described (12).
Serially diluted sterile solution of immunoglobulin was
incubated with 100 plaque-forming units (PFU) of EMC
virus at 37°C for 1 h. The reaction was stopped at 4°C for
30 min. The sample was added to confluent monolayers of
VERO (African green monkey kidney) cells in six-well
plastic plates. After two days of incubation at 37°C, the cells
were fixed with acetic acid and methanol and stained with
crystal violet; then the plaques were counted. Plaque forma-
tion was expressed as a percentage of the number of control
plaques (12).
In vivo study. INFECTION PROTOCOL. The virus stock of
EMC virus prepared in cultures of VERO cells in Eagle’s
minimum essential medium (13). Virus suspensions were
centrifuged after the cytopathic effect had developed, and
the viral stock had a titer of .109 PFU/ml determined in
tissue cultures.
Four-week-old male, inbred, certified virus-free DBA/2
mice (Shizuoka Laboratory Animal Center) were used. The
animals were inoculated intraperitoneally with 0.1 ml virus
suspension containing 10 PFU. The studies were approved
by the institution’s Animal Care and Use Committee.
TREATMENT PROTOCOL. Immunoglobulin was adminis-
tered intraperitoneally daily; the actual dose in each exper-
iment was calculated from the mouse weight at the begin-
ning of the experiment. As determined from previous
studies (1,2,12), the dose of immunoglobulin used was
1 g/kg/day.
EXPERIMENT I. Sixty mice were randomized to two groups
that received either no treatment (n 5 30) or treatment with
immunoglobulin (n 5 30). Mice in the untreated group
were injected intraperitoneally with 0.1 ml saline during the
treatment period.
Treatment was begun simultaneously with the virus
inoculation and was given for 14 days. The mice were
observed daily, and necropsy was performed immediately on
those found dead. Seven mice in each group were killed on
day 7 for virological study and for an age-matched study of
cardiac pathology. Accordingly, the survival study covered
23 mice in each of the two groups. Mice surviving until the
end of the treatment period were killed and the organs were
processed for pathological study.
Two additional control groups consisted of uninfected
mice treated for 14 days with saline (n 5 3) and with
immunoglobulin (n 5 3).
EXPERIMENT II. Mice surviving until 14 days after virus
inoculation (n 5 40) were randomized to either of two
groups: no treatment (n 5 20) or treatment with immuno-
globulin (n 5 20). Treatment was given for 14 days, i.e.,
until 28 days after virus inoculation. Five mice in each group
were killed on day 21 for cardiac pathology. Accordingly,
the survival study covered 15 mice in each of the two groups.
The mice were observed daily, and necropsy was carried out
on those that died during the course of the experiment. At
the end of the treatment period, the same procedure as in
experiment I was performed.
Two additional control groups consisted of age-matched
uninfected mice treated for 14 days with saline (n 5 3) and
with immunoglobulin (n 5 3) in parallel with the study
protocol.
PATHOLOGICAL STUDY. Hearts were snap-frozen or em-
bedded in paraffin. The heart sections were stained with
hematoxylin-eosin to identify active myocardial necrosis and
with Masson’s trichrome to identify repairing fibrosis.
Fibrin was demmstrated in situ by direct immunoperoxidase
staining with the use of an antibody to mouse fibrin (14).
The histological sections were examined and the extent of
inflammatory lymphocyte infiltration and active myocardial
necrosis was evaluated semiquantitatively on a scale of 11 to
41. In addition, fibrin deposition and fibrosis were quan-
tified using computer-assisted image analysis as previously
described (14). In brief, microscopic images were studied
with an Olympus BX50 microscope (Tokyo, Japan)
equipped with a video camera (Olympus ICD-740-1) con-
nected to a color video monitor. A digitized tablet was used
and an image analysis software package was used for
morphometric analysis.
To avoid postmortem changes and to match the time
course, pathological studies were performed only on mice
euthanized on days 7, 14, 21 and 28.
VIROLOGICAL STUDY. For the infectivity assay, portions of
the heart were weighed and homogenized aseptically. After
a 15-min centrifugation at 1,500 g, virus titers in the
supernatants were determined by a plaque assay method as
previously described (12,14).
CATECHOLAMINE ASSAY. Plasma catecholamines (norepi-
nephrine and epinephrine) were quantitated using reverse-
phase high-pressure liquid chromatography with electro-
chemical detection. Plasma was deproteinized with 1.0 N
HCL and centrifuged at 18,000 g for 10 min at 4°C. The
resulting perchloric acid extracts were frozen at 280°C until
analysis could be performed.
Abbreviations and Acronyms
EMC virus 5 encephalomyocarditis virus
E 5 epinephrine
IFN-g 5 interferon-g
NE 5 norepinephrine
PFU 5 plaque-forming units
sICAM-1 5 soluble intercellular adhesion molecule-1
VERO cells 5 African green monkey kidney cells
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CYTOKINE ASSAY. Plasma interferon-gamma (IFN-g) and
soluble intercellular adhesion molecule 21 (sICAM-1)
were determined using antibody-sandwich enzyme-linked
immunosorbent assay.
STATISTICAL ANALYSIS. Student t test for unpaired obser-
vation and chi-square analysis with Yates’ correction were
used to evaluate differences in the study variables. A p value
,0.05 was considered statistically significant.
RESULTS
In vitro study. The percent plaque formation was 92.9 6
9.3% at an immunoglobulin concentration of 1023.0 mg/ml,
93.0 6 10.6% at 1022.0mg/ml, 94.4 6 9.5% at 1021.0mg/
ml, and 97.6 6 6.3% at 100 mg/ml (each n 5 5). There was
no correlation between PFU and the immunoglobulin
concentrations. Thus, immunoglobulin (Polyglobin-N)
does not contain a significant amount of antibodies against
EMC virus.
In vivo study. MORTALITY. In experiment I, the survival
rate of the immunoglobulin-treated group was significantly
higher (p , 0.05) than that of the untreated control group.
Survival rate on day 14 in each group was as follows: control
group 43.5% (10/23) and immunoglobulin group 78.3%
(18/23). In experiment II, the survival rate of the
immunoglobulin-treated group was higher (p , 0.05)
compared with that of controls. Survival rate on day 28 in
each group was as follows: control group 60.0% (9/15) and
immunoglobulin group 93.3% (14/15).
There were no deaths throughout the treatment period in
either uninfected (immunoglobulin-treated or untreated)
group in experiments I and II.
CARDIAC PATHOLOGY (TABLE 1, FIGURE 1). In experiment
I on days 7 and 14, both cellular infiltration and myo-
cardial necrosis were significantly less severe in the
immunoglobulin-treated group compared with the un-
treated group. In experiment II on days 21 and 28, both
scores in the immunoglobulin-treated group were lower
than those of the untreated group.
Figure 1. Photominographs showing representative abnormalities of fibrin
deposition and myocardial fibrosis in heart of a mouse with myocarditis in
Experiment I (day 14). Interstitial fibrin deposition (A, arrows) and fibrosis
(B, blue) in areas of myocardial necrosis in untreated group was more severe
than in immunoglobulin-treated group (C, D). A, C 5 Immunoperoxidase
stain for fibrin; B, D 5 Masson’s trichrome stain for fibrosis: A, B, C,
D 3120.
Table 1. Cardiac Pathology
(11 to 41) (%)
Infiltration Necrosis Fibrin Fibrosis
Experiment I
Day 7
Control 2.43 6 0.79 (n 5 7) 2.14 6 0.69 6.0 6 2.0 (n 5 5) ND
Immunoglobulin 1.43 6 0.53* (n 5 7) 1.14 6 0.38† 1.6 6 0.9† (n 5 5) ND
Day 14
Control 3.20 6 0.79 (n 5 10) 2.80 6 0.63 24.8 6 5.0 (n 5 5) 5.6 6 1.8
Immunoglobulin 2.20 6 0.65† (n 5 18) 2.10 6 0.58† 5.6 6 2.0† (n 5 5) 1.8 6 0.8†
Experiment II
Day 21
Control 3.20 6 0.45 (n 5 5) 2.60 6 0.55 12.6 6 3.3 (n 5 5) 12.0 6 3.5
Immunoglobulin 1.80 6 0.84* (n 5 5) 1.2 6 0.45† 5.0 6 1.6† (n 5 5) 5.0 6 1.5†
Day 28
Control 1.67 6 0.71 (n 5 9) 1.89 6 0.60 7.8 6 1.6 (n 5 5) 22.8 6 4.8
Immunoglobulin 1.07 6 0.73* (n 5 14) 0.93 6 0.73† 2.6 6 1.1† (n 5 5) 6.0 6 2.0†
Myocardial lesions were graded on a scale of 11 to 41 to determine the severity of cellular infiltration and myocardial necrosis. Fibrin deposition and fibrosis were quantified
using a computer-assisted image analysis, as previously described (14). ND, not determined. *p , 0.05, †p , 0.01 vs. control. (mean 6 SD).
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In experiments I and II, fibrin deposition was signifi-
cantly less in the treated than in the control groups. In
addition, fibrosis was less severe in the treated than in the
control groups in both experiments.
There was no abnormal finding in the myocardium in
each uninfected (immunoglobulin or untreated) group in
experiments I and II.
MYOCARDIAL VIRUS TITERS. Myocardial virus titers of
immunoglobulin-treated mice were not statistically different
from those of controls in experiments I and II (data not
shown).
CATECHOLAMINE LEVELS (TABLE 2). Norepinephrine and
epinephrine were significantly lower in the immunoglobulin-
treated than in the untreated groups in experiments I and II.
Catecholamine levels were significantly greater in the virus-
infected mice than in the uninfected (control) mice (data
not shown).
CYTOKINES LEVELS (TABLE 2). In experiments I and II,
IFN-g and sICAM-1 were significantly lower in the
immunoglobulin-treated than in the untreated groups.
DISCUSSION
This study showed that immunoglobulin treatment suffi-
ciently ameliorated murine EMC viral myocarditis associ-
ated with reduction of plasma neurohumoral factors and
improvement of extracellular matrix remodeling. The in
vitro study showed the absence of neutralizing anti-EMC
viral antibodies in the immunoglobulin used in this study.
Thus, immunoglobulin could suppress EMC viral myocar-
ditis, not by an antiviral effect, but by neurohumoral
modification.
Role of immunoglobulin therapy. The role of immuno-
globulin in the therapy of myocarditis or acute dilated
cardiomyopathies is not fully understood (15–18). Although
idiopathic dilated cardiomyopathy is a heterogenous disor-
der, most patients are suspected of sharing a similar viral/
autoimmune pathogenesis (8,19,20) and may benefit from
immune modulatory therapy.
It is possible that immunoglobulin administration may
alter immune responses, thus leading to a decrease in cardiac
inflammation. The accepted mechanism of action is reticu-
loendothelial system blockade (1,2). Reticuloendothelial
system blockade implies that high concentrations of immu-
noglobulin could prevent antigen presentation and stimula-
tion of immune responses by several mechanisms. Poly-
clonal immunoglobulin may bind to Fc receptors on
macrophages and prevent internalization of the antigens.
Exogenous proteins may occupy phagocytic vesicles to the
exclusion of autoantigens, thus inhibiting autoimmune pro-
cesses. An overabundance of immunoglobulin peptides may
competitively prevent autoantigen peptides from binding to
relevant major histocompatibility class I or II molecules.
Polyclonal immunoglobulin-treated macrophages may show
deficiencies in inflammatory cytokine secretion (1,2).
Myocardial damage in myocarditis. Numerous studies are
being performed to elucidate the mechanisms of myocardial
damage in myocarditis. Increasing evidence suggests that
cytotoxic T cells (21), neurohumoral factors (22), inflam-
matory cytokines (23) and free radicals, possibly generated
by infiltrating cells in the myocardium, play a significant
role, separately or together, in the development of myocar-
dial damage and dysfunction in addition to the primary
damage caused by viral infection.
A direct connection between viral myocarditis and car-
diomyopathy in humans has remained elusive (19). Studies
in experimental animals have provided direct evidence to
support this causal relationship and have brought us pro-
gressively closer to understanding some of the mechanisms
whereby viral infection in the heart may trigger specific
pathologic and immunologic responses (6,12,14,20–24).
The experimental studies have documented the late devel-
opment of myocardial fibrosis (9,10). However, the mech-
anisms responsible for this cardiac remodeling are unknown.
Fibrin gels, when placed in the subcutaneous tissue of
Table 2. Neurohumoral Data
NE (pg/ml) E (pg/ml) IFN-g (pg/ml) sICAM-1 (mg/ml)
Experiment I
Day 7
Control — — 1,860 6 640 (n 5 7) —
Immunoglobulin — — 700 6 280* (n 5 7)
Day 14
Control 6,360 6 1,930 (n 5 5) 3,380 6 1,510 — 16.7 6 2.1 (n 5 5)
Immunoglobulin 2,140 6 730* (n 5 7) 640 6 370* — 11.6 6 1.1* (n 5 7)
Experiment II
Day 21
Control — — 580 6 160 (n 5 5) —
Immunoglobulin — — 220 6 80* (n 5 5) —
Day 28
Control 4,750 6 1,720 (n 5 4) 1,830 6 450 — 12.7 6 1.9 (n 5 5)
Immunoglobulin 1,070 6 470* (n 5 7) 260 6 150* — 7.3 6 1.7* (n 5 7)
Plasma catecholamines were assayed using reverse-phase high-pressure liquid chromatography. Cytokines were determined using antibody sandwich enzyme-linked
immunosorbent assay. E indicates epinephrine; INF-g, interferon-g; NE, norepinephrine; sICAM-1, soluble intercellular adhesion molecule-1. *p , 0.01 vs control. (mean 6
SD).
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animals, elicit an angiogenetic and connective tissue re-
sponse characterized by the formation of new blood vessels
and the immigration of macrophages and fibroblasts, fol-
lowed by the local synthesis of collagen and the deposition
of collagen matrix (9,10). Extravasated fibrin may function
as a template for the deposition of collagen during healing
of the inflammation (24,25).
Immunoglobulin therapy in myocarditis. Our previous
study demonstrated that immunoglobulin therapy sup-
presses coxsackievirus B3 myocarditis by transferring the
neutralizing antibody into the host in the acute stage,
because human immunoglobulin contains the antibody
against coxsackievirus B3, which is most common in hu-
mans (12). The present study was performed to evaluate
mechanisms of immunoglobulin other than its neutralizing
activity against viruses, because EMC virus is an enterovirus
of the family Picornaviridae (13) and not pathogenic to
humans. The results showed that immunoglobulin therapy
could suppress EMC virus myocarditis not by EMC virus
neutralizing activity but by the reduction of plasma cat-
echolamines, IFN-g, and sICAM-1.
The findings of the present study have shown that
immunoglobulin ameliorated EMC viral myocarditis via its
effect on neurohumoral factors in the period of congestive
heart failure (experiment II) and in the early stage (experi-
ment I). Although we neither examined the pathology of
the central nervous system nor detected viruses in the brain,
the possibility of involvement of the central nervous system
by a cardiotropic EMC virus used in this study may be low
(13). Therefore, we consider that the activation of the
sympathetic system was due to severe heart failure; subse-
quent immunoglobulin injection decreases plasma cat-
echolamines, suggesting that immunoglobulin exerts its
cardioprotective effect through sympathetic modulating ac-
tions.
Neurohumoral activation in heart failure. The response
to immunoglobulin appeared to be mediated by the sympa-
thetic nervous system. The involvement of the sympathetic
nervous system in heart failure caused by myocarditis has
been addressed in number of earlier studies. For example, in
animals with congestive heart failure caused by myocarditis,
a relative limitation of the sympathetic activity might be
present. In addition, studies in other models have impli-
cated the involvement of catecholamines and the sympa-
thetic nervous system (26). In the present study, neurohu-
moral activation was used as a clinical marker for congestive
heart failure, and thus the observed effects on cat-
echolamines by immunoglobulin administration are indi-
rect.
The reduction of IFN-g and sICAM-1 by immunoglob-
ulin administration was reported as a therapeutic possible
mechanism in some inflammatory diseases, because immu-
noglobulin itself contains antibodies against cytokines (1,2).
Also, suppression of cytokine-dependent T-cell prolifera-
tion by immunoglobulin treatment in vitro and in inflam-
matory disorders was demonstrated (27–29).
In a number of pathologic processes that result in fibrosis,
such as wound healing and the generation of tumor stroma,
extravascular fibrin deposition precedes collagen formation
or fibrosis. In these processes, fibrin gel with inflammatory
cytokines, i.e., IFN-g and sICAM-1, serves as a provisional
matrix for angiogenesis, inflammatory cell and fibroblast
migration, and subsequently fibrosis (11,24,25). We have
already investigated interstitial fibrin deposition and myo-
cardial fibrosis in a murine model in which myocarditis was
caused by another cardiotropic virus, coxsackievirus B3 (14).
It was reported that elevated plasma catecholamines and
cytokines in heart failure may increase or change capillary
permeability, which in turn triggers the extravasation of
fibrin into the interstitium (12,24–26). The improvement of
connective tissue abnormalities by immunoglobulin treat-
ment demonstrated in the present study may be due, in part,
to the suppressions of increased capillary permeability.
Study limitations. In this study, the virus was isolated only
by a conventional biological method instead of with the
polymerase chain reaction. Accordingly, the possibility of
the so-called persistent virus infection could not be com-
pletely excluded in experiment II.
Conclusions. Immunoglobulin therapy could suppress
myocarditis not only by anticardiotopic viral effects but also
by anti-inflammatory effects associated with the reduction
of plasma catecholamines as well as IFN-g and sICAM-1.
This leads to the improvement of the structural changes of
extracellular matrix.
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